Mr Neil Barber was appointed as Consultant Urological Surgeon to Frimley Park Hospital in 2005 with a remit to deliver core urology but also specialist care in the fields of BPH and renal cancer, over the last 20 years, Mr Barber has been at the forefront of changes in these fields

As Director of the Frimley Renal Cancer Service overseeing the introduction of both the Da Vinci and Versius robotic platforms to the trust and the delivery of the highest number of robotic assisted partial nephrectomy per year in the UK. Having established the Frimley Benign Prostate Clinical Research Centre, Mr Barber has led and been involved in all the clinical trials in this rapidly evolving field, facilitating the introduction of Greenlight laser, Urolift, iTIND, and most recently Aquablation to the UK. He is a globally recognised key opinion leader, lecturing and teaching all over the world, including the European School of Urology, and has sat as a clinical expert for NICE for plasma TURP, Greenlight laser, Urolift, Rezum, iTIND, and Aquablation.

Mr Barber continues to lead or be involved in all ongoing and planned high quality trials in this field and as a member of the GIRFT BPH committee and working with NHS England, he has helped develop both new guidelines and patient information animations to improve BPH management and treatment across the UK. As one of the highest volume BPH surgeons in Europe, he has performed Aquablation of the prostate since 2015 and many hundreds of cases and remains enthusiastic and involved in the future development of this exciting new technology. He continues to work to bring new technology to patients across the speciality with the overarching aim to offer patients the highest quality care.

Five-year outcomes for Aquablation therapy compared to TURP: results from a double-blind, randomized trial in men with LUTS due to BPH. Gilling PJ, Barber N, Bidair M, Anderson P, Sutton M, Aho T, Kramolowsky E, Thomas A, Kaufman RP Jr, Badlani G, Plante M, Desai M, Doumanian L, Te AE, Roehrborn CG. Can J Urol. 2022 Feb;29(1):10960-10968.

Second generation of temporary implantable nitinol device (iTind) in men with LUTS: 2 year results of the MT-02-study. Kadner G, Valerio M, Giannakis I, Manit A, Lumen N, Ho BSH, Alonso S, Schulman C, Barber N, Amparore D, Porpiglia F. World J Urol. 2020 Dec;38(12):3235-3244

A Multicentre Analysis of the Detection of Clinically Significant Prostate Cancer Following Transperineal Image-fusion Targeted and Nontargeted Systematic Prostate Biopsy in Men at Risk.

Miah S, Hosking-Jervis F, Connor MJ, Eldred-Evans D, Shah TT, Arya M, Barber N, Bhardwa J, Bott S, Burke D, Doherty A, Foster C, Freeman A, Hindley R, Jameson C, Karim O, Laniado M, Montgomery B, Nigam R, Punwani S, Sinclair A, Winkler M, Allen C, Ahmed HU. Eur Urol Oncol. 2019 Mar 29. pii: S2588-9311(19)30038-0.

‘Prostatic urethral lift vs transurethral resection of the prostate: 2-year results of the BPH6 prospective, multicentre, randomized study.’ Gratzke C, Barber N, Speakman MJ, Berges R, Wetterauer U, Greene D, Sievert KD, Chapple CR, Patterson JM, Fahrenkrug L, Schoenthaler M, Sonksen J. BJU Int. 2017 May;119(5):767-775

‘A Multicenter Randomized Noninferiority Trial Comparing GreenLight-XPS Laser Vaporization of the Prostate and Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Obstruction: Two-yr Outcomes of the GOLIATH Study.’ Thomas JA, Tubaro A, Barber N et al, Eur Urol. 2016 Jan;69(1):94-102